Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 2,854Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 7Trajenta

02 1Trajenta / Jentadueto

03 3Trajenta/ Jentadueto

04 3Trajenta/Jentadueto

PharmaCompass

01

Brand Name : Trajenta/ Jentadueto

Linagliptin

arrow
American Pharma Summit
Not Confirmed

Brand Name : Trajenta/ Jentadueto

arrow
American Pharma Summit
Not Confirmed

Linagliptin

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 1,801

2019 Revenue in Millions : 1,857

Growth (%) : -3

blank

02

Brand Name : Trajenta

Linagliptin

arrow
American Pharma Summit
Not Confirmed

03

Brand Name : Trajenta/ Jentadueto

Linagliptin

arrow
American Pharma Summit
Not Confirmed

Brand Name : Trajenta/ Jentadueto

arrow
American Pharma Summit
Not Confirmed

Linagliptin

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 1,709

2020 Revenue in Millions : 1,801

Growth (%) : 3

blank

04

Brand Name : Trajenta

Linagliptin

arrow
American Pharma Summit
Not Confirmed

05

Brand Name : Trajenta/Jentadueto

Linagliptin

arrow
American Pharma Summit
Not Confirmed

Brand Name : Trajenta/Jentadueto

arrow
American Pharma Summit
Not Confirmed

Linagliptin

Main Therapeutic Indication : Diabetes

Currency : USD

2022 Revenue in Millions : 1,846

2021 Revenue in Millions : 1,709

Growth (%) : 8

blank

06

Brand Name : Trajenta/Jentadueto

Linagliptin

arrow
American Pharma Summit
Not Confirmed

Brand Name : Trajenta/Jentadueto

arrow
American Pharma Summit
Not Confirmed

Linagliptin

Main Therapeutic Indication : Diabetes

Currency : USD

2023 Revenue in Millions : 1,816

2022 Revenue in Millions : 1,846

Growth (%) : 0

blank

07

Brand Name : Trajenta

Linagliptin

arrow
American Pharma Summit
Not Confirmed

08

Brand Name : Trajenta/Jentadueto

Linagliptin

arrow
American Pharma Summit
Not Confirmed

Brand Name : Trajenta/Jentadueto

arrow
American Pharma Summit
Not Confirmed

Linagliptin

Main Therapeutic Indication : Diabetes

Currency : USD

2016 Revenue in Millions : 1,196

2015 Revenue in Millions : 964

Growth (%) : 24

blank

09

Brand Name : Trajenta / Jentadueto

Linagliptin

arrow
American Pharma Summit
Not Confirmed

Brand Name : Trajenta / Jentadueto

arrow
American Pharma Summit
Not Confirmed

Linagliptin

Main Therapeutic Indication : Diabetes

Currency : USD

2018 Revenue in Millions : 1,579

2017 Revenue in Millions : 1,506

Growth (%) : 5%

blank

10

Brand Name : Trajenta/ Jentadueto

Linagliptin

arrow
American Pharma Summit
Not Confirmed

Brand Name : Trajenta/ Jentadueto

arrow
American Pharma Summit
Not Confirmed

Linagliptin

Main Therapeutic Indication : Diabetes

Currency : USD

2019 Revenue in Millions : 1,699

2018 Revenue in Millions : 1,523

Growth (%) : 12

blank